Woodline Partners’s CytomX Therapeutics CTMX Stock Holding History

Woodline Partners’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.65M	Buy	2,040,210 +39,385	+2%	+$150K	0.02%	597
2026 Q1	$9.4M	Sell	2,000,825 -336,180	-14%	-$1.71M	0.04%	527
2025 Q4	$9.96M	Hold	2,337,005	–	–	0.04%	464
2025 Q3	$7.46M	Buy	2,337,005 +106	+0%	+$239	0.04%	496
2025 Q2	$5.3M	Buy	2,336,899 +679,593	+41%	+$1.1M	0.03%	544
2025 Q1	$1.05M	Buy	+1,657,306	New	+$1.29M	0.01%	763
2024 Q4	–	Sell	-393,832	Closed	-$465K	–	949
2024 Q3	$465K	Buy	+393,832	New	+$500K	﹤0.01%	542

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Woodline Partners's CTMX Position: Q2 2026 in Review

Woodline Partners increased its CytomX Therapeutics (CTMX) stake by 2% in Q2 2026, buying an estimated $150K and bringing the position to 2,040,210 shares worth $7.65M. The position accounts for 0.02% of the portfolio, ranked #597.

Woodline Partners first reported a position in CTMX in Q3 2024 and has held it in 7 quarters since. The position peaked at $9.96M in Q4 2025. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Woodline Partners held 2,040,210 shares of CytomX Therapeutics worth $7.65M as of Q2 2026.
Woodline Partners bought 39,385 CytomX Therapeutics shares in Q2 2026, an estimated $150K.
CytomX Therapeutics made up 0.02% of Woodline Partners's portfolio in Q2 2026, its #597 holding.
Woodline Partners first reported a position in CytomX Therapeutics in Q3 2024 and has held it in 7 quarters since.
Woodline Partners's CytomX Therapeutics position peaked at $9.96M in Q4 2025.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.